Long-term nephrotoxicity in adult survivors of childhood cancer

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 6, 2013, Pages 922-929

  Dekkers, Ilona A ^a   Blijdorp, Karin ^a,b   Cransberg, Karlien ^a   Pluijm, Saskia M ^a   Pieters, Rob ^a   Neggers, Sebastian J ^a,b   van den Heuvel Eibrink, Marry M ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CISPLATIN; CREATININE; IFOSFAMIDE;

ADULT; ARTICLE; BLOOD PRESSURE; CHILDHOOD CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; IRRADIATION; KIDNEY TUBULE FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NEPHRECTOMY; NEPHROTOXICITY; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; ALBUMINURIA; ANTINEOPLASTIC AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CREATININE; CROSS-SECTIONAL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IFOSFAMIDE; KIDNEY; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; NEPHRECTOMY; ODDS RATIO; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS; TIME FACTORS; YOUNG ADULT;

EID: 84878825222     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09980912     Document Type: Article

References (47)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D,Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241, 2012
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005
3. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, Mertens AC: Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 27: 2328-2338, 2009
4. Oeffinger KC,Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL; Childhood Cancer Survivor Study: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355: 1572-1582, 2006
5. Jones DP, Spunt SL, Green D, Springate JE; Children's Oncology Group: Renal late effects in patients treated for cancer in childhood: A report from the Children's Oncology Group. Pediatr Blood Cancer 51: 724-731, 2008
6. Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M: Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol 57: 393-402, 2001
7. Ho PT, Zimmerman K,Wexler LH, Blaney S, Jarosinski P,Weaver- McClure L, Izraeli S, Balis FM: A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer 76: 2557-2564, 1995
8. Jones DP, Chesney RW: Renal toxicity of cancer chemotherapeutic agents in children: Ifosfamide and cisplatin. Curr Opin Pediatr 7: 208-213, 1995
9. Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, Ragab A, Wharam M, Wiener E, Maurer H: Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. Am J Pediatr Hematol Oncol 16: 286-295, 1994
10. Skinner R, Cotterill SJ, Stevens MC; United Kingdom Children's Cancer Study Group: Risk factors for nephrotoxicity after ifosfamide treatment in children: AUKCCSG Late Effects Group study. Br J Cancer 82: 1636-1645, 2000
11. Skinner R: Nephrotoxicity-what dowe knowand what don't we know? J Pediatr Hematol Oncol 33: 128-134, 2011
12. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16: 489-495, 2005
13. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63: 1121-1129, 2003
14. Shlipak MG, Fried LF, Crump C, Bleyer AJ,Manolio TA, Tracy RP, Furberg CD, Psaty BM: Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 62: 997-1004, 2002
15. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative metaanalysis. Lancet 375: 2073-2081, 2010
16. van der Velde M,Matsushita K, Coresh J, Astor BC,Woodward M, Levey A, de Jong P, Gansevoort RT, van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, Levey A, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T; Chronic Kidney Disease Prognosis Consortium: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 79: 1341-1352, 2011
17. Chobanian AV, Bakris GL,Black HR,Cushman WC,Green LA, Izzo JL Jr, Jones DW,Materson BJ,Oparil S,Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment ofHighBlood Pressure.NationalHeart, Lung, andBlood Institute; National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on Prevention,Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252, 2003
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
19. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: 137-147, 2003
20. Levey AS, Coresh J,Greene T,Marsh J, Stevens LA, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration: Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53: 766-772, 2007
21. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M: Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. Kidney Int 72: 632-637, 2007
22. Schwab SJ, Christensen RL,Dougherty K, Klahr S:Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 147: 943-944, 1987
23. de Zeeuw D, Hillege HL, de Jong PE: The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl 98: S25-S29, 2005
24. Skinner R: Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 41: 190-197, 2003
25. Womer RB, Pritchard J, Barratt TM: Renal toxicity of cisplatin in children. J Pediatr 106: 659-663, 1985
26. Hartmann JT, Fels LM, Franzke A, Knop S, Renn M, Maess B, Panagiotou P, Lampe H, Kanz L, Stolte H, Bokemeyer C: Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide. Anticancer Res 20[5C]: 3767-3773, 2000
27. Rossi R, Kleta R, Ehrich JH: Renal involvement in children with malignancies. Pediatr Nephrol 13: 153-162, 1999
28. Knijnenburg SL, Jaspers MW, van der Pal HJ, Schouten-Vanmeeteren AY, Bouts AH, Lieverst JA, Bokenkamp A, Koning CC, Oldenburger F, Wilde JC, van Leeuwen FE, Caron HN, Kremer LC: Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors. Clin J Am Soc Nephrol 7: 1416-1427, 2012
29. Birn H, Christensen EI: Renal albumin absorption in physiology and pathology. Kidney Int 69: 440-449, 2006
30. Maunsbach AB: Albumin absorption by renal proximal tubule cells. Nature 212: 546-547, 1966
31. Burton CJ, Combe C,Walls J, Harris KP: Secretion of chemokines and cytokines by human tubular epithelial cells in response to proteins. Nephrol Dial Transplant 14: 2628-2633, 1999
32. Morais C, Westhuyzen J, Metharom P, Healy H: High molecular weight plasma proteins induce apoptosis and Fas/FasL expression in human proximal tubular cells. Nephrol Dial Transplant 20: 50-58, 2005
33. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH: Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14: 1-10, 2003
34. Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH: Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 40: 41-62, 2001
35. Ciarimboli G, Holle SK, Vollenbrocker B, Hagos Y, Reuter S, Burckhardt G, Bierer S, Herrmann E, Pavenstadt H, Rossi R, Kleta R, Schlatter E: New clues for nephrotoxicity induced by ifosfamide: Preferential renal uptake via the human organic cation transporter 2. Mol Pharm 8: 270-279, 2011
36. Malempati S, Hawkins DS: Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. Pediatr Blood Cancer 59: 5-10, 2012
37. Lie Fong S, Laven JS, Hakvoort-Cammel FG, Schipper I, Visser JA, Themmen AP, de Jong FH, van den Heuvel-Eibrink MM: Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mü llerian hormone. Hum Reprod 24: 982-990, 2009
38. Lie Fong S, van den Heuvel-Eibrink MM, Eijkemans MJ, Schipper I, Hukkelhoven CW, Laven JS: Pregnancy outcome in female childhood cancer survivors. Hum Reprod 25: 1206-1212, 2010
39. Hempel L, Misselwitz J, Fleck C, Kentouche K, Leder C, Appenroth D, Rost M, Zintl F: Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 40: 348-354, 2003
40. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC: High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100: 2222-2232, 2004
41. Brenner BM, Meyer TW, Hostetter TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl JMed 307: 652-659, 1982
42. Dols LF, Weimar W, Ijzermans JN: Long-term consequences of kidney donation. N Engl J Med 360: 2371-2372, 2009
43. Garg AX, Muirhead N, Knoll G, Yang RC, Prasad GV, Thiessen- Philbrook H, Rosas-Arellano MP, Housawi A, Boudville N; Donor Nephrectomy Outcomes Research (DONOR) Network: Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression. Kidney Int 70: 1801-1810, 2006
44. Baudoin P, Provoost AP, Molenaar JC: Renal function up to 50 years after unilateral nephrectomy in childhood. AmJ KidneyDis 21: 603-611, 1993
45. Haddy TB, Mosher RB, Reaman GH: Hypertension and prehypertension in long-termsurvivors of childhood and adolescent cancer. Pediatr Blood Cancer 49: 79-83, 2007
46. Neville KA, Cohn RJ, Steinbeck KS, Johnston K, Walker JL: Hyperinsulinemia, impaired glucose tolerance, and diabetes mellitus in survivors of childhood cancer: Prevalence and risk factors. J Clin Endocrinol Metab 91: 4401-4407, 2006
47. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110: 2809-2816, 2004